<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK65707" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK65707/" /><meta name="ncbi_pagename" content="Pseudohypoaldosteronism Type II - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Pseudohypoaldosteronism Type II - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Pseudohypoaldosteronism Type II" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/02/16" /><meta name="citation_author" content="David H Ellison" /><meta name="citation_pmid" content="22073419" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65707/" /><meta name="citation_keywords" content="Familial Hyperkalemic Hypertension" /><meta name="citation_keywords" content="Gordon's Syndrome" /><meta name="citation_keywords" content="PHAII" /><meta name="citation_keywords" content="PHAII" /><meta name="citation_keywords" content="Gordon’s Syndrome" /><meta name="citation_keywords" content="Familial Hyperkalemic Hypertension" /><meta name="citation_keywords" content="Cullin-3" /><meta name="citation_keywords" content="Kelch-like protein 3" /><meta name="citation_keywords" content="Serine/threonine-protein kinase WNK1" /><meta name="citation_keywords" content="Serine/threonine-protein kinase WNK4" /><meta name="citation_keywords" content="CUL3" /><meta name="citation_keywords" content="KLHL3" /><meta name="citation_keywords" content="WNK1" /><meta name="citation_keywords" content="WNK4" /><meta name="citation_keywords" content="Pseudohypoaldosteronism Type II" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Pseudohypoaldosteronism Type II" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="David H Ellison" /><meta name="DC.Date" content="2017/02/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65707/" /><meta name="description" content="Pseudohypoaldosteronism type II (PHAII) is characterized by hyperkalemia despite normal glomerular filtration rate (GFR) and frequently by hypertension. Other associated findings in both children and adults include hyperchloremia, metabolic acidosis, and suppressed plasma renin levels. Aldosterone levels are variable, but are relatively low given the degree of hyperkalemia (elevated serum potassium is a potent stimulus for aldosterone secretion). Hypercalciuria is well described." /><meta name="og:title" content="Pseudohypoaldosteronism Type II" /><meta name="og:type" content="book" /><meta name="og:description" content="Pseudohypoaldosteronism type II (PHAII) is characterized by hyperkalemia despite normal glomerular filtration rate (GFR) and frequently by hypertension. Other associated findings in both children and adults include hyperchloremia, metabolic acidosis, and suppressed plasma renin levels. Aldosterone levels are variable, but are relatively low given the degree of hyperkalemia (elevated serum potassium is a potent stimulus for aldosterone secretion). Hypercalciuria is well described." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65707/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pha2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65707/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D7591E04153810000000001B300AB.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK65707_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK65707_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/psach/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pxe/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK65707_"><span class="title" itemprop="name">Pseudohypoaldosteronism Type II</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Hyperkalemic Hypertension, Gordon's Syndrome, PHAII</div><p class="contrib-group"><span itemprop="author">David H Ellison</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK65707_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK65707_ai__"><div class="contrib half_rhythm"><span itemprop="author">David H Ellison</span>, MD<div class="affiliation small">Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@dnosille" class="oemail">ude.usho@dnosille</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 10, 2011</span>; Last Update: <span itemprop="dateModified">February 16, 2017</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pha2.Summary" itemprop="description"><h2 id="_pha2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Pseudohypoaldosteronism type II (PHAII) is characterized by hyperkalemia despite normal glomerular filtration rate (GFR) and frequently by hypertension. Other associated findings in both children and adults include hyperchloremia, metabolic acidosis, and suppressed plasma renin levels. Aldosterone levels are variable, but are relatively low given the degree of hyperkalemia (elevated serum potassium is a potent stimulus for aldosterone secretion). Hypercalciuria is well described.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of PHAII is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>:</p><ul><li class="half_rhythm"><div class="half_rhythm">With hyperkalemia (in the setting of normal glomerular filtration), hypertension, metabolic acidosis, hyperchloremia, and suppressed plasma renin levels;</div><div class="half_rhythm">AND/OR</div></li><li class="half_rhythm"><div class="half_rhythm">By the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CUL3</i>, <i>WNK1</i>, or <i>WNK4</i> or a heterozygous pathogenic variant or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>KLHL3</i>.</div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Electrolyte and blood pressure abnormalities of PHAII in children and adults are often corrected with thiazide diuretics.</p><p><i>Prevention of secondary complications:</i> Control of blood pressure is important to reduce the risk of cardiovascular and renal disease and stroke.</p><p><i>Surveillance:</i> Routine electrolyte and blood pressure measurements.</p><p><i>Agents/circumstances to avoid</i>: Untreated individuals with PHAII should avoid excessive intake of foods high in salt and potassium as these may exacerbate hypertension and hyperkalemia.</p><p><i>Evaluation of relatives at risk:</i> Measurement of serum potassium concentration and blood pressure or identification of the known <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, and <i>WNK4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in first-degree relatives of individuals with PHAII allows for early diagnosis and treatment .</p><p><i>Pregnancy management:</i> Affected pregnant women should undergo routine monitoring of electrolytes and blood pressure, with adjustments to antihypertensive medication dosage as needed. Some antihypertensive medications, including thiazide diuretics, have been associated with adverse fetal outcome, especially when taken during the first trimester of pregnancy; referral to an obstetrics group with expertise in high-risk pregnancies should be considered.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PHAII is frequently inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; PHAIID (caused by pathogenic variants in <i>KLHL3</i>) may also be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Many pathogenic variants in <i>CUL3</i> arise <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> and are not inherited from a parent. Each child of an individual with autosomal dominant PHAII has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant(s) in the family is known.</p></div></div><div id="pha2.Diagnosis"><h2 id="_pha2_Diagnosis_">Diagnosis</h2><p>No formal diagnostic criteria for PHAII have been published.</p><div id="pha2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Pseudohypoaldosteronism type II (PHAII) <b>should be suspected</b> in individuals with the following clinical features, supportive laboratory findings, and family history.</p><p><b>Clinical features.</b> Hypertension (blood pressure &#x0003e;140/90 mm Hg) generally manifesting in adolescence or adulthood but also reported in children. Note: The absence of frank hypertension does not preclude the diagnosis.</p><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div>Hyperkalemia in the absence of impaired glomerular filtration</div><ul><li class="half_rhythm"><div>Serum concentration of potassium ranges from mildly (serum K ~5.0-6.0 mmol/L) to severely elevated (&#x0003e;8.0 mmol/L) (normal range: ~3.5-5.1 mmol/L).</div></li><li class="half_rhythm"><div>This finding is nearly universal in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals at all ages.</div></li></ul></li><li class="half_rhythm"><div>Metabolic acidosis: serum concentration of bicarbonate ranging from 14 to 24 mmol/L (normal range: ~22-29 mmol/L)</div></li><li class="half_rhythm"><div>Hyperchloremia: serum concentration of chloride ranging from 105 to 117 mmol/L (normal range: ~99-108 mmol/L)</div></li><li class="half_rhythm"><div>Suppressed plasma renin levels</div></li><li class="half_rhythm"><div>Variable serum aldosterone levels that tend to be relatively suppressed in the context of hyperkalemia</div></li><li class="half_rhythm"><div>Serum calcium and parathyroid hormone levels that are normal. However, hypercalciuria is noted in at least a subset of individuals.</div></li></ul><p><b>Family history.</b> A <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with similar findings. Note: Absence of a family history of a first-degree relative with similar findings does not preclude the diagnosis.</p></div><div id="pha2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of PHAII <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with hyperkalemia (in the setting of normal glomerular filtration) often accompanied by hypertension, metabolic acidosis, hyperchloremia, and suppressed plasma renin levels <b>and/or</b> by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>KLHL3</i> (see <a class="figpopup" href="/books/NBK65707/table/pha2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpha2Tmoleculargenetictestingusedin" rid-ob="figobpha2Tmoleculargenetictestingusedin">Table 1</a>). Note: PHAII is sometimes referred to by a subtype designation based on the associated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>; see <a href="#pha2.Nomenclature">Nomenclature</a>.</p><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div>It is reasonable to perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> for pathogenic variants in <i>CUL3</i> and/or <i>KLHL3</i> first.</div></li><li class="half_rhythm"><div>If only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KLHL3</i> is identified in an individual in whom <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance is suspected, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>KLHL3</i> should be considered.</div></li><li class="half_rhythm"><div>Sequence analysis of <i>WNK4</i> may be performed next.</div></li><li class="half_rhythm"><div>If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified through sequencing of <i>WNK4</i>, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>WNK1</i> may be considered next.</div></li><li class="half_rhythm"><div>If no disease-causing <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> is found in <i>WNK1</i>, consider sequencing of <i>WNK1</i>.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, and <i>WNK4</i> and other genes of interest (see <a href="#pha2.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="pha2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Pseudohypoaldosteronism Type II</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65707/table/pha2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pha2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of PHAII Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CUL3</i></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25/86 families reported</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All reported cases to date</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KLHL3</i></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41/86 families reported&#x000a0;<sup>5</sup></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autosomal dominant: 29/86<br />Autosomal recessive: 12/86</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>WNK1</i></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/86 families reported</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/2&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>WNK4</i></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/86 families reported</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All reported cases to date</td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/52&#x000a0;<sup>10</sup></td><td headers="hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_pha2.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pha2.TF.1.1"><p class="no_margin">See <a href="/books/NBK65707/#pha2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pha2.TF.1.2"><p class="no_margin">See <a href="#pha2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="pha2.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="pha2.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="pha2.TF.1.5"><p class="no_margin">Both <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>) and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>) pathogenic variants in <i>KLHL3</i> cause PHAII [<a class="bk_pop" href="#pha2.REF.mayan.2004.4025">Mayan et al 2004</a>, <a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.picard.2015a.e79">Picard et al 2015a</a>, <a class="bk_pop" href="#pha2.REF.mitani.2016.127">Mitani et al 2016</a>].</p></div></dd><dt>6. </dt><dd><div id="pha2.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>7. </dt><dd><div id="pha2.TF.1.7"><p class="no_margin">Recently, six kindreds (9 individuals) were reported in preliminary results to have pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>WNK1</i> (detailed in <a href="#pha2.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd><dt>8. </dt><dd><div id="pha2.TF.1.8"><p class="no_margin">Two large deletions have been reported (see <a href="#pha2.Molecular_Genetics">Molecular Genetics</a>) [<a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al 2001</a>].</p></div></dd><dt>9. </dt><dd><div id="pha2.TF.1.9"><p class="no_margin">An additional <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> on 1q31-q42 has been identified as harboring a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> associated with PHAII [<a class="bk_pop" href="#pha2.REF.mansfield.1997.202">Mansfield et al 1997</a>]. The identity of this gene is unknown. PHAII has been reported in at least ten families that lack identifiable pathogenic variants in <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, and <i>WNK4</i> [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.glover.2014.721">Glover et al 2014</a>].</p></div></dd><dt>10. </dt><dd><div id="pha2.TF.1.10"><p class="no_margin">Denominator is from the only report to document the number of PHAII individuals who did not have variants in <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>].</p></div></dd></dl></div></div></div></div></div><div id="pha2.Clinical_Characteristics"><h2 id="_pha2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="pha2.Clinical_Description"><h3>Clinical Description</h3><p>Pseudohypoaldosteronism type II (PHAII) is characterized by hyperkalemia despite normal glomerular filtration rate (GFR) and frequently by hypertension. More than 180 individuals and families with PHAII have been reported.</p><p>The clinical presentation of PHAII is heterogeneous. The most consistent clinical feature in both children and young adults is hyperkalemia [<a class="bk_pop" href="#pha2.REF.gordon.1986.93">Gordon 1986</a>]. As with essential hypertension, blood pressure is usually normal in young persons, with hypertension developing later in life. Untreated individuals with elevated blood pressure are at risk of developing complications of hypertension including cardiac disease, renal impairment, and stroke.</p><p>Other associated findings in both children and adults include hyperchloremia, metabolic acidosis, and suppressed plasma renin levels. Aldosterone levels are variable, but are relatively low given the degree of hyperkalemia (elevated serum potassium is a potent stimulus for aldosterone secretion). Hypercalciuria is also well described in PHAII [<a class="bk_pop" href="#pha2.REF.mayan.2004.4025">Mayan et al 2004</a>].</p><p>Other features reported in a subset of individuals with PHAII include short stature, myalgias, periodic paralysis, and dental abnormalities [<a class="bk_pop" href="#pha2.REF.gordon.1986.93">Gordon 1986</a>]. It has been suggested that these findings may be more prevalent in individuals with severe hyperkalemia and metabolic acidosis; however, exceptions have been reported [<a class="bk_pop" href="#pha2.REF.gordon.1986.93">Gordon 1986</a>, <a class="bk_pop" href="#pha2.REF.farfel.2011.1547">Farfel et al 2011</a>].</p></div><div id="pha2.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>CUL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> tend to have more severe hyperkalemia and metabolic acidosis, earlier development of hypertension, and greater likelihood of growth impairment compared to those harboring <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> alterations [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>].</p><p>In general, clinical manifestations of PHAII appear to be milder in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>WNK1</i> or <i>WNK4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> compared to those with a heterozygous <i>CUL3</i> or a heterozygous or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>KLHL3</i> pathogenic variant(s) [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>].</p><p>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>KLHL3</i> pathogenic variants may have a more severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KLHL3</i> [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.louisditpicard.2012">Louis-Dit-Picard et al 2012</a>].</p></div><div id="pha2.Nomenclature"><h3>Nomenclature</h3><p>The term "pseudohypoaldosteronism" has historically been used to describe the finding of persistent hyperkalemia despite the presence of normal or elevated serum levels of aldosterone [<a class="bk_pop" href="#pha2.REF.schambelan.1981.716">Schambelan et al 1981</a>]. The term was initially used to describe persons with an inherited disorder characterized by hyperkalemia, elevated serum aldosterone, and volume depletion (now referred to as pseudohypoaldosteronism type I).</p><p>Therefore, the term "pseudohypoaldosteronism" is a misnomer in the context of PHAII, as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have hyperkalemia with hypertension (instead of volume depletion). Some authorities prefer the descriptive name <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hyperkalemic hypertension (FHHt) for this reason.</p><p>PHAII is sometimes referred to by a subtype designation based on the associated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, as follows:</p><ul><li class="half_rhythm"><div>PHA type IIA (PHA2A): Unknown genetic cause (see <a class="figpopup" href="/books/NBK65707/table/pha2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpha2Tmoleculargenetictestingusedin" rid-ob="figobpha2Tmoleculargenetictestingusedin">Table 1</a>, footnotes 9 and 10)</div></li><li class="half_rhythm"><div>PHA type IIB (PHA2B): <i>WNK4</i></div></li><li class="half_rhythm"><div>PHA type IIC (PHA2C): <i>WNK1</i></div></li><li class="half_rhythm"><div>PHA type IIE (PHA2E): <i>CUL3</i></div></li><li class="half_rhythm"><div>PHA type IID (PHA2D): <i>KLHL3</i></div></li></ul></div><div id="pha2.Prevalence"><h3>Prevalence</h3><p>The prevalence of the disorder is unknown. To date more than 180 individuals and families with PHAII have been reported.</p></div></div><div id="pha2.Genetically_Related_Allelic_Disorde"><h2 id="_pha2_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b><i>WNK1.</i></b>
<a href="/books/n/gene/hsan2/">Hereditary sensory and autonomic neuropathy type IIA</a> (HSAN2A) is associated with apparent loss-of function variants in specific exons of <i>WNK1</i>. Missense variants in <i>WNK1</i> have been reported in association with hypokalemic salt-losing tubulopathy in two unrelated individuals [<a class="bk_pop" href="#pha2.REF.zhang.2013.545">Zhang et al 2013</a>].</p><p><b><i>CUL3</i>, <i>KLHL3</i>,</b>
<b><i>WNK4.</i></b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>CUL3</i>, <i>KLHL3</i>, or <i>WNK4.</i></p></div><div id="pha2.Differential_Diagnosis"><h2 id="_pha2_Differential_Diagnosis_">Differential Diagnosis</h2><p>Hyperkalemia resulting from the following can generally be distinguished from hyperkalemia caused by PHAII on the basis of plasma renin levels, which are increased in the following conditions and suppressed in PHAII.</p><p>Other causes of hyperkalemia:</p><ul><li class="half_rhythm"><div>Chronic kidney disease, especially when secondary to diabetes, is the most commonly identified cause of hyperkalemia.</div></li><li class="half_rhythm"><div>When renal function is normal, consider the following:</div><ul><li class="half_rhythm"><div>Hypoaldosteronism or acquired renal tubular acidosis (type 4), particularly in the setting of marked volume depletion</div></li><li class="half_rhythm"><div>Medication effects. Examples include potassium-sparing diuretics (e.g., spironolactone), nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin inhibitors, trimethoprim, and cyclosporine.</div></li><li class="half_rhythm"><div>Primary adrenal insufficiency or deficiency of an adrenal synthetic enzyme</div></li></ul></li></ul></div><div id="pha2.Management"><h2 id="_pha2_Management_">Management</h2><div id="pha2.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with pseudohypoaldosteronism type II (PHAII), the following evaluations are recommended, if not performed as part of the diagnostic evaluation:</p><ul><li class="half_rhythm"><div>Serum electrolyte analysis</div></li><li class="half_rhythm"><div>Noninvasive blood pressure measurement</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="pha2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Electrolyte and blood pressure abnormalities of PHAII are often corrected with thiazide diuretics. Metabolic abnormalities and hypertension generally improve within one week.</p><p>Different thiazide diuretics exist, with different dosing regimens. In general dosing is titrated to normalization of blood pressure. It is possible that dosing will need to be increased over time or that additional anti-hypertensives will be required to adequately control blood pressure.</p><p>There are no established guidelines regarding age at which treatment should begin for individuals with PHAII, but <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children who have hypertension are generally treated.</p></div><div id="pha2.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>See <a href="#pha2.Treatment_of_Manifestations">Treatment of Manifestations</a>.</p></div><div id="pha2.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Control of blood pressure is important to reduce the risk for cardiovascular and renal disease and stroke.</p></div><div id="pha2.Surveillance"><h3>Surveillance</h3><p>Appropriate surveillance includes routine electrolyte and blood pressure measurements, monitored in the same manner as for any person treated with a thiazide diuretic.</p></div><div id="pha2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Untreated individuals with PHAII should avoid excessive intake of foods high in salt and potassium as these may exacerbate hypertension and hyperkalemia.</p></div><div id="pha2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from prompt initiation of treatment. Evaluations can include:</p><ul><li class="half_rhythm"><div>Measurement of serum potassium concentration and blood pressure;</div></li><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known.</div></li></ul><p>See <a href="#pha2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pha2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>During the pregnancy of a woman with PHAII, electrolytes and blood pressure should be monitored regularly and blood pressure medication adjusted as needed.</p><p>Some antihypertensive medications (including thiazide diuretics) have been associated with adverse fetal outcome, especially when taken during the first trimester of pregnancy. The best time to discuss the risk to the fetus associated with a maternal medication is prior to conception. Women with PHAII who become pregnant should be referred to an obstetrics group with expertise in high-risk pregnancies.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="pha2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://www.ClinicalTrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="pha2.Genetic_Counseling"><h2 id="_pha2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pha2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Pseudohypoaldosteronism type II (PHAII) is most commonly inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. PHAIID can also be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="pha2.Risk_to_Family_Members__Autosomal_D"><h3>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Many individuals diagnosed with PHAII have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with PHAII may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#pha2.REF.gong.2008.230">Gong et al 2008</a>].</div><div class="half_rhythm">Fifteen of 182 reported cases have been <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>; 14/15 caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <i>CUL3</i> variant and 1/15 caused by a heterozygous <i>KLHL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.tsuji.2013.166">Tsuji et al 2013</a>, <a class="bk_pop" href="#pha2.REF.picard.2015a.e79">Picard et al 2015a</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include clinical evaluation (electrolyte analysis and blood pressure measurement) and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if a <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> pathogenic variant has been identified in the proband.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (although no instances of germline mosaicism have been reported, it remains a possibility).</div></li><li class="half_rhythm"><div class="half_rhythm">Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure to recognize the syndrome as a result of a milder phenotypic presentation, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents: if a parent of the proband is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. However, the sibs of a proband with clinically unaffected parents are still at increased risk for PHAII because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with PHAII has a 50% chance of inheriting the <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="pha2.Risk_to_Family_Members__Autosomal_R"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>KLHL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Carriers of a <i>KLHL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> PHAIID are typically asymptomatic and do not appear to be at risk of developing the disorder; however, thorough clinical analysis of such individuals over time has not been reported.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Carriers of a <i>KLHL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> PHAIID are typically asymptomatic and are not thought to be at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> PHAIID are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KLHL3</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>KLHL3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Carrier (<a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>) detection.</b> Carrier testing for at-risk relatives requires prior identification of the <i>KLHL3</i> pathogenic variants in the family.</p></div><div id="pha2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#pha2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pha2.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CUL3</i>, <i>KLHL3</i>, <i>WNK1</i>, or <i>WNK4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for PHAII are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While decisions regarding prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="pha2.Resources"><h2 id="_pha2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Genetic Disorders of Mucociliary Clearance Consortium (GDMCC)</b></div><div>Cystic Fibrosis / Pulmonary Research &#x00026; Treatment Center</div><div>Marsico Lung Institute</div><div>7215 Marsico Hall</div><div>CB #7248</div><div>Chapel Hill NC 27599-7248</div><div><b>Fax:</b> 919-966-7524; 919-843-5309</div><div><b>Email:</b> godwine@med.unc.edu; kelli_sullivan@med.unc.edu</div><div><a href="https://www.rarediseasesnetwork.org/cms/gdmcc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Genetic Diseases Of Mucociliary Clearance Consortium</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li></ul></div><div id="pha2.Molecular_Genetics"><h2 id="_pha2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pha2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Pseudohypoaldosteronism Type II: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65707/table/pha2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pha2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pha2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pha2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pha2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pha2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pha2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pha2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pha2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8452" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CUL3</i></a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q36<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13618" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cullin-3</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_pha2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CUL3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CUL3</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CUL3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CUL3</a></td></tr><tr><td headers="hd_b_pha2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/26249" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KLHL3</i></a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=26249" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5q31<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UH77" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Kelch-like protein 3</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/KLHL3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KLHL3 @ LOVD</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KLHL3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KLHL3</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KLHL3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KLHL3</a></td></tr><tr><td headers="hd_b_pha2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/65125" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>WNK1</i></a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=65125" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p13<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9H4A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase WNK1</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=33" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, HSN2</a><br /><a href="http://www.LOVD.nl/WNK1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK1 @ LOVD</a><br /><a href="https://databases.lovd.nl/shared/genes/WNK1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK1 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=WNK1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK1</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=WNK1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK1</a></td></tr><tr><td headers="hd_b_pha2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/65266" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>WNK4</i></a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=65266" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q96J92" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase WNK4</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/WNK4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK4 database</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=WNK4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK4</a></td><td headers="hd_b_pha2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=WNK4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WNK4</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pha2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pha2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Pseudohypoaldosteronism Type II (<a href="/omim/145260,601844,603136,605232,605775,614491,614492,614495,614496" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65707/table/pha2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pha2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/145260" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">145260</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601844" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601844</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEIN KINASE, LYSINE-DEFICIENT 4; WNK4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603136" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603136</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CULLIN 3; CUL3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605232" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605232</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEIN KINASE, LYSINE-DEFICIENT 1; WNK1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605775" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605775</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KELCH-LIKE 3; KLHL3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614491" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614491</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSEUDOHYPOALDOSTERONISM, TYPE IIB; PHA2B</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614492" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614492</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSEUDOHYPOALDOSTERONISM, TYPE IIC; PHA2C</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614495" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614495</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614496" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614496</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E</td></tr></tbody></table></div></div><div id="pha2.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Pathogenic variants in the genes encoding two members of the WNK protein family of serine-threonine kinases, <i>WNK1</i> and <i>WNK4</i>, have been implicated in the pathogenesis of pseudohypoaldosteronism type II (PHAII) [<a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al 2001</a>]. Members of this kinase family are named WNK (or <i>w</i>ith <i>n</i>o lysine [<i>K</i>]) kinases because of their unique substitution of cysteine for lysine at a highly conserved residue within the catalytic kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#pha2.REF.xu.2000.16795">Xu et al 2000</a>]. Over the past decade, members of the WNK kinase family have been shown to regulate the coordinated transport of Na<sup>+</sup>, K<sup>+</sup>, and Cl<sup>-</sup> ions across epithelia in a variety of tissues [<a class="bk_pop" href="#pha2.REF.kahle.2008.91">Kahle et al 2008</a>].</p><p>Alterations in <i>WNK1</i> and <i>WNK4</i> are present in only a minority of individuals with PHAII, motivating the search for additional genetic contributions to the disorder in other families. Recently, pathogenic variants in kelch-like 3 (<i>KLHL3</i>) and cullin 3 (<i>CUL3</i>) have been identified in the majority of families with PHAII [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.louisditpicard.2012">Louis-Dit-Picard et al 2012</a>]. The protein products of <i>CUL3</i> and <i>KLHL3</i> function together as part of the cullin-RING E3 ubiquitin ligase complex, which has a role in ubiquitin-mediated protein degradation.</p><p>The electrolyte and blood pressure abnormalities in individuals with PHAII are readily corrected with thiazide diuretics, inhibitors of the Na-Cl cotransporter (NCC; encoded by <i>SLC12A3</i>) expressed in the renal distal convoluted and connecting tubules (see Management, <a href="#pha2.Treatment_of_Manifestations">Treatment of Manifestations</a>). This clinical observation led to the initial hypothesis that increased activity of NCC could play a role in the pathogenesis of PHAII [<a class="bk_pop" href="#pha2.REF.gordon.1986.93">Gordon 1986</a>]. However, to date, no PHAII-causing variants in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding NCC have been demonstrated.</p><div id="pha2.CUL3"><h4><i>CUL3</i></h4><p><b>Gene structure.</b>
<i>CUL3</i> is widely expressed and has several alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK65707/#pha2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b>
<i>CUL3</i> alterations causing PHAII occur within <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 8, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9, or intron 9 and disrupt <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of exon 9. This results in a 57-amino acid <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> CUL3 is a component of the cullin-RING E3 ubiquitin ligase complex, which functions in ubiquitin-mediated proteolysis. Immunostaining of mouse kidney demonstrates that CUL3 is present throughout the nephron [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> It has been suggested that <i>CUL3</i> pathogenic variants in PHAII may disrupt ubiquitination of at least a subset of KLHL3 targets [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>]. The observation that all reported <i>CUL3</i> pathogenic variants impair <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9 and result in an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of a segment of <i>CUL3</i> may hint at the functional specificity of these pathogenic variants [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>].</p></div><div id="pha2.KLHL3"><h4><i>KLHL3</i></h4><p><b>Gene structure.</b>
<i>KLHL3</i> is widely expressed with at least three alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> reported. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK65707/#pha2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Dominant <i>KLHL3</i> pathogenic variants that cause PHAII are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> alternations that cluster in segments connecting beta-strands of Kelch propeller blades within the C-terminal Kelch propeller <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and disrupt substrate binding.</p><p>Recessive <i>KLHL3</i> pathogenic variants occur throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and include frameshift and premature termination variants.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> KLHL3 is a component of the cullin-RING E3 ubiquitin ligase complex, which functions in ubiquitin-mediated proteolysis. KLHL3 contains an N-terminal bric-a-brac tramtrack broad complex (BTB) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that has a role in binding to CUL3 and a BTB and C-terminal Kelch (BACK) domain. KLHL3 also contains a C-terminal six-bladed Kelch propeller domain that functions in substrate binding.</p><p>Wild type KLHL3 has been shown to bind to WNK4 and WNK1 [<a class="bk_pop" href="#pha2.REF.ohta.2013.111">Ohta et al 2013</a>, <a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wakabayashi.2013.858">Wakabayashi et al 2013</a>]. Furthermore, binding of KLHL3 to WNK4 has been shown to result in ubiquitination and degradation of WNK4 in vitro, suggesting that KLHL3 normally regulates WNK4 levels via ubiquitin-mediated proteolysis [<a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wakabayashi.2013.858">Wakabayashi et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wu.2013.1717">Wu &#x00026; Peng 2013</a>]. Expression of KLHL3 together with binding of KLHL3 to WNK1 has also been shown to result in ubiquitination of WNK1 [<a class="bk_pop" href="#pha2.REF.ohta.2013.111">Ohta et al 2013</a>].</p><p>Immunostaining of mouse kidney demonstrates that KLHL3 is predominantly present in the distal convoluted tubule and collecting duct [<a class="bk_pop" href="#pha2.REF.boyden.2012.98">Boyden et al 2012</a>, <a class="bk_pop" href="#pha2.REF.louisditpicard.2012">Louis-Dit-Picard et al 2012</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Missense variants in <i>KLHL3</i> that cause PHAII disrupt binding to WNK4, WNK1, or CUL3 and lead to decreased ubiquitination and increased levels of WNK4 [<a class="bk_pop" href="#pha2.REF.mori.2013.30">Mori et al 2013</a>, <a class="bk_pop" href="#pha2.REF.ohta.2013.111">Ohta et al 2013</a>, <a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wakabayashi.2013.858">Wakabayashi et al 2013</a>]. Mutated KLHL3 has also been shown to decrease WNK4-mediated clearance of ROMK from the cell membrane [<a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>].</p></div><div id="pha2.WNK1"><h4><i>WNK1</i></h4><p><b>Gene structure.</b>
<i>WNK1</i> transcript variant 1 (reference sequence <a href="/nuccore/NM_018979.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_018979.3</a>) has 30 exons and encodes the most common protein isoform. Alternatively spliced transcript variants have been described; the full-length nature of all of them has yet to be determined. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK65707/#pha2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants in <i>WNK1</i> were initially reported in two families with PHAII [<a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al 2001</a>]. Both are large deletions (41 kb and 21 kb) that occur within the 60-kb <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 of <i>WNK1</i>. The deletions do not affect the coding sequence of the flanking exons. Recently, 6 kindreds (9 individuals) were reported to have pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>WNK1</i>, coupled with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that includes hyperkalemia and acidosis; the hypertension was minimal. The pathogenic missense variants clustered in the region homologous to the acidic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> mutated in <i>WNK4</i> [<a class="bk_pop" href="#pha2.REF.picard.2015b.e1">Picard et al 2015b</a>].</p><div id="pha2.T.selected_wnk1_pathogenic_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>WNK1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65707/table/pha2.T.selected_wnk1_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pha2.T.selected_wnk1_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">g.18538_59810del&#x000a0;<sup>1,2</sup></td><td headers="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NG_007984.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NG_007984<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">g.28500_50277del&#x000a0;<sup>2</sup></td><td headers="hd_h_pha2.T.selected_wnk1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="pha2.TF.2.1"><p class="no_margin">Deletion within <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 (also known as NG_007984.2:c.759+12272_760-5774del)</p></div></dd><dt>2. </dt><dd><div id="pha2.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al [2001]</a></p></div></dd><dt>3. </dt><dd><div id="pha2.TF.2.3"><p class="no_margin">No amino acid change is expected.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>WNK1</i> encodes at least four different alternatively spliced <i>WNK1</i> transcripts (See see <a href="/books/NBK65707/#pha2.molgen.TA">Table A</a>, <b>Gene</b> further details). The interplay between these <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> is complex. Two variants were initially identified: a longer isoform with ubiquitous tissue expression (L-WNK1) and a smaller isoform that lacks the 5' kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the larger isoform and appears to be kidney-specific (KS-WNK1) [<a class="bk_pop" href="#pha2.REF.delaloy.2003.9208">Delaloy et al 2003</a>, <a class="bk_pop" href="#pha2.REF.oreilly.2003.2447">O'Reilly et al 2003</a>]. A neuronal isoform of WNK1 (termed WNK1/HSN2) that is highly expressed in the cell body of sensory ganglia neurons and neuronal projections has been identified. Pathogenic variants in an alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> of the transcript that encodes this isoform cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a href="/books/n/gene/hsan2/">hereditary sensory and autonomic neuropathy type 2</a>, a disorder of progressive sensory deficit to touch, temperature, and pain [<a class="bk_pop" href="#pha2.REF.shekarabi.2008.2496">Shekarabi et al 2008</a>].</p><p>The L-Wnk1 isoform can activate the kinase SPAK (encoded by <i>STK39</i>), which in turn can phosphorylate and activate NCC (the Na-Cl cotransporter) encoded by <i>SLC12A3</i>. The KS-WNK1 isoform, expressed predominantly along the distal nephron, binds to and inhibits the activity of L-Wnk1 in <i>Xenopus</i> [<a class="bk_pop" href="#pha2.REF.subramanya.2006.f619">Subramanya et al 2006</a>] and transgenic mice [<a class="bk_pop" href="#pha2.REF.liu.2011.855">Liu et al 2011</a>]. WNK1 can also interact, through a conserved "HQ" <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, with other WNK kinases, including WNK4. These interactions have complex functional effects [<a class="bk_pop" href="#pha2.REF.yang.2003.1039">Yang et al 2003</a>, <a class="bk_pop" href="#pha2.REF.ch_vezcanales.2014.1047">Ch&#x000e1;vez-Canales et al 2014</a>].</p><p>As a multifunctional regulator of ion channels and transporters, WNK1 also inhibits the K<sup>+</sup> channel ROMK1, encoded by <i>KCNJ1</i> [<a class="bk_pop" href="#pha2.REF.liu.2009.12198">Liu et al 2009</a>] and (probably via phosphorylation of downstream kinase SGK-1) activates the amiloride-sensitive Na<sup>+</sup> channel ENaC encoded by <i>SCNN1A</i>, <i>SCNN1B</i>, and <i>SCNN1G</i> [<a class="bk_pop" href="#pha2.REF.xu.2005.10315">Xu et al 2005</a>, <a class="bk_pop" href="#pha2.REF.hadchouel.2010.18109">Hadchouel et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Both of the known <i>WNK1</i> deletions causing PHAII occur within the first <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> of the gene and do not affect the amino acid structure of the gene product(s). It was initially shown that <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> within the first intron increases <i>WNK1</i> transcription in peripheral leukocytes [<a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al 2001</a>]. Subsequent work demonstrated that the intron deletion leads to increased L-WNK1 expression in the distal convoluted tubule [<a class="bk_pop" href="#pha2.REF.vidalpetiot.2013.14366">Vidal-Petiot et al 2013</a>]. These findings support the hypothesis that the deletion within the first intron leads to increased expression of L-WNK1, which should phosphorylate and stimulate NCC.</p><p>A knockout mouse model of L-WNK1 has also been generated, and mice with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> targeted disruption of the L-<i>Wnk1</i> transcript have significantly decreased blood pressure compared to wild type [<a class="bk_pop" href="#pha2.REF.zambrowicz.2003.14109">Zambrowicz et al 2003</a>]. Mice with targeted disruption of KS<i>-Wnk1</i> exhibited increased activity of NCC, altered function of the ROMK (encoded by <a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6255" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>KCNJ1</i></a>) and BKCa potassium channels, and decreased ENaC expression [<a class="bk_pop" href="#pha2.REF.hadchouel.2010.18109">Hadchouel et al 2010</a>], confirming previous in vitro observations.</p></div><div id="pha2.WNK4"><h4><i>WNK4</i></h4><p><b>Gene structure.</b>
<i>WNK4</i> has 19 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK65707/#pha2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> All reported pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> alterations. All pathogenic variants reported to date have been identified in exons 7 and 17 [<a class="bk_pop" href="#pha2.REF.wilson.2001.1107">Wilson et al 2001</a>, <a class="bk_pop" href="#pha2.REF.golbang.2005.295">Golbang et al 2005</a>, <a class="bk_pop" href="#pha2.REF.brooks.2012.791">Brooks et al 2012</a>].</p><div id="pha2.T.selected_wnk4_pathogenic_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>WNK4</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65707/table/pha2.T.selected_wnk4_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pha2.T.selected_wnk4_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1679A&#x0003e;G</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu560Gly</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_3" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_032387.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_032387<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_115763.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_115763<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1682C&#x0003e;T</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro561Leu</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1684G&#x0003e;A</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu562Lys</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1690G&#x0003e;C</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp564His</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1691A&#x0003e;C</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp564Ala</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1693C&#x0003e;G</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln565Glu</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3505A&#x0003e;G</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys1169Glu</td></tr><tr><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3553C&#x0003e;T</td><td headers="hd_h_pha2.T.selected_wnk4_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1185Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>WNK4</i> product is a 1,243-amino acid protein encoded by a 3,732-nucleotide <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> within a 4-kb <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> transcript. Northern blot analysis showed expression primarily within the kidney, but immunofluorescence studies have shown the protein is present in the epithelial lining of a variety of tissues including the colon, liver, and pancreas [<a class="bk_pop" href="#pha2.REF.kahle.2004a.2064">Kahle et al 2004a</a>].</p><p>WNK4 has been shown to regulate the activity of a number of ion transporters through heterologous expression in <i>Xenopus</i> oocytes and in mammalian cell systems [<a class="bk_pop" href="#pha2.REF.kahle.2008.91">Kahle et al 2008</a>]. The major effect of WNK4 in vivo appears to be stimulation of NCC; it may also inhibit ROMK [<a class="bk_pop" href="#pha2.REF.kahle.2003.372">Kahle et al 2003</a>, <a class="bk_pop" href="#pha2.REF.wilson.2003.680">Wilson et al 2003</a>]. WNK4 has also been reported to increase paracellular chloride permeability in mammalian kidney cells via claudin phosphorylation [<a class="bk_pop" href="#pha2.REF.kahle.2004b.14877">Kahle et al 2004b</a>, <a class="bk_pop" href="#pha2.REF.yamauchi.2004.4690">Yamauchi et al 2004</a>, <a class="bk_pop" href="#pha2.REF.tatum.2007.3887">Tatum et al 2007</a>]. Like WNK1, WNK4 also regulates other structurally diverse but functionally related ion channels including ENaC [<a class="bk_pop" href="#pha2.REF.ring.2007a.4020">Ring et al 2007a</a>, <a class="bk_pop" href="#pha2.REF.ring.2007b.4025">Ring et al 2007b</a>] and the cation nonselective TRP channels TRPV4 and TRPV5 [<a class="bk_pop" href="#pha2.REF.fu.2006.f1305">Fu et al 2006</a>]. Deletion of WNK4 results in a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that resembles Gitelman syndrome, indicating that the predominant WNK4 effect in vivo is stimulation of NCC [<a class="bk_pop" href="#pha2.REF.casta_edabueno.2012.7929">Casta&#x000f1;eda-Bueno et al 2012</a>, <a class="bk_pop" href="#pha2.REF.takahashi.2014">Takahashi et al 2014</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The effects of PHAII-associated <i>WNK4</i> pathogenic variants on the above targets have been evaluated in vitro in oocytes and mammalian cells and in vivo in mouse models [reviewed in <a class="bk_pop" href="#pha2.REF.ch_vezcanales.2014.1047">Ch&#x000e1;vez-Canales et al 2014</a>].</p><p>Important information about the mechanisms underlying <i>WNK4</i>-related PHAII came from the development and characterization of mouse models of PHAII [<a class="bk_pop" href="#pha2.REF.lalioti.2006.1124">Lalioti et al 2006</a>, <a class="bk_pop" href="#pha2.REF.yang.2007.331">Yang et al 2007</a>]. Mice transgenic for a chromosomal segment encoding the murine <i>Wnk4</i> with a Gln562Glu <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (orthologous to the human p.Gln565Glu pathogenic variant) had hyperkalemia, higher blood pressure, and hypercalciuria compared to mice transgenic for a chromosomal segment encoding wild type <i>Wnk4</i> [<a class="bk_pop" href="#pha2.REF.lalioti.2006.1124">Lalioti et al 2006</a>]. In addition, marked hyperplasia of the distal convoluted tubule (DCT) and increased expression of NCC were noted in mutated <i>Wnk4</i> transgenic mice but not in wild type <i>Wnk4</i> transgenic mice. All abnormalities were entirely corrected when mutated <i>Wnk4</i> transgenic mice were crossed with mice harboring a targeted disruption of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding NCC, indicating that the effect of mutated <i>Wnk4</i> on NCC activity alone is sufficient to cause the PHAII <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Essentially similar findings were reported in a mouse <i>Wnk4</i> mutated knock-in model of PHAII [<a class="bk_pop" href="#pha2.REF.yang.2007.331">Yang et al 2007</a>].</p><p>Most PHAII-causing variants in WNK4 cluster within a highly conserved non-catalytic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> just distal to the kinase domain. Recent in vitro studies have demonstrated that this segment is critical for binding to KLHL3, and PHAII-associated variants within this domain disrupt interactions between WNK4 and KLHL3 [<a class="bk_pop" href="#pha2.REF.ohta.2013.111">Ohta et al 2013</a>, <a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wakabayashi.2013.858">Wakabayashi et al 2013</a>]. Due to the role of KLHL3 in ubiquitin-mediated proteolysis (see <a href="#pha2.KLHL3"><i>KLHL3</i></a>), this should lead to increased WNK4 levels. Indeed, increased WNK4 levels are reported in the WNK4 mouse models of PHAII discussed above [<a class="bk_pop" href="#pha2.REF.shibata.2013.7838">Shibata et al 2013</a>, <a class="bk_pop" href="#pha2.REF.wakabayashi.2013.858">Wakabayashi et al 2013</a>].</p><p>It has also been suggested that pathogenic variants within this segment disrupt a calcium-sensing mechanism important in the regulation of WNK4 kinase activity [<a class="bk_pop" href="#pha2.REF.na.2012.293">Na et al 2012</a>]. Similarly, the PHAII-associated p.Arg1185Cys <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (located near the C-terminus of WNK4 and separate from this <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>) has also been implicated in impaired calcium sensing and altered phosphorylation by SGK1 [<a class="bk_pop" href="#pha2.REF.na.2013.f8">Na et al 2013</a>].</p></div></div></div><div id="pha2.References"><h2 id="_pha2_References_">References</h2><div id="pha2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.boyden.2012.98">Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Valimaki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, David ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TRP, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. <span><span class="ref-journal">Nature. </span>2012;<span class="ref-vol">482</span>:98–102.</span> [<a href="/pmc/articles/PMC3278668/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278668</span></a>] [<a href="/pubmed/22266938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22266938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.brooks.2012.791">Brooks AM, Owens M, Sayer JA, Salzmann M, Ellard S, Vaidya B. Pseudohypoaldosteronism type 2 presenting with hypertension and hyperkalaemia due to a novel mutation in the WNK4 gene. <span><span class="ref-journal">QJM. </span>2012;<span class="ref-vol">105</span>:791–4.</span> [<a href="/pubmed/21764813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21764813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.casta_edabueno.2012.7929">Casta&#x000f1;eda-Bueno M, Cervantes-P&#x000e9;rez LG, V&#x000e1;zquez N, Uribe N, Kantesaria S, Morla L, Bobadilla NA, Doucet A, Alessi DR, Gamba G. Activation of the renal Na+:Cl- cotransporter by angiotensin II is a WNK4-dependent process. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2012;<span class="ref-vol">109</span>:7929–34.</span> [<a href="/pmc/articles/PMC3356635/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3356635</span></a>] [<a href="/pubmed/22550170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22550170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.ch_vezcanales.2014.1047">Ch&#x000e1;vez-Canales M, Zhang C, Soukaseum C, Moreno E, Pacheco-Alvarez D, Vidal-Petiot E, Casta&#x000f1;eda-Bueno M, V&#x000e1;zquez N, Rojas-Vega L, Meermeier NP, Rogers S, Jeunemaitre X, Yang CL, Ellison DH, Gamba G, Hadchouel J. WNK-SPAK-NCC cascade revisited: WNK1 stimulates the activity of the Na-Cl cotransporter via SPAK, an effect antagonized by WNK4. <span><span class="ref-journal">Hypertension. </span>2014;<span class="ref-vol">64</span>:1047–53.</span> [<a href="/pmc/articles/PMC5832045/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5832045</span></a>] [<a href="/pubmed/25113964" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25113964</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.delaloy.2003.9208">Delaloy C, Lu J, Houot AM, Disse-Nicodeme S, Gasc JM, Corvol P, Jeunemaitre X. Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. <span><span class="ref-journal">Mol Cell Biol. </span>2003;<span class="ref-vol">23</span>:9208–21.</span> [<a href="/pmc/articles/PMC309643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC309643</span></a>] [<a href="/pubmed/14645531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14645531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.farfel.2011.1547">Farfel A, Mayan H, Melnikov S, Holtzman EJ, Pinhas-Hamiel O, Farfel Z. Effect of age and affection status on blood pressure, serum potassium and stature in familial hyperkalaemia and hypertension. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2011;<span class="ref-vol">26</span>:1547–53.</span> [<a href="/pubmed/20956807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20956807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.fu.2006.f1305">Fu Y, Subramanya A, Rozansky D, Cohen DM. WNK kinases influence TRPV4 channel function and localization. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2006;<span class="ref-vol">290</span>:F1305–14.</span> [<a href="/pubmed/16403833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16403833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.glover.2014.721">Glover M, Ware JS, Henry A, Wolley M, Walsh R, Wain LV, Xu S, Van't Hoff WG, Tobin MD, Hall IP, Cook S, Gordon RD, Stowasser M, O'Shaughnessy KM. Detection of mutations in KLHL3 and CUL3 in families with familial hyperkalaemic hypertension (FHHt or Gordon syndrome). <span><span class="ref-journal">Clin Sci (Lond). </span>2014;<span class="ref-vol">126</span>:721–6.</span> [<a href="/pmc/articles/PMC3963521/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3963521</span></a>] [<a href="/pubmed/24266877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24266877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.golbang.2005.295">Golbang AP, Murthy M, Hamad A, Liu CH, Cope G, Van't Hoff W, Cuthbert A, O'Shaughnessy KM. A new kindred with pseudohypoaldosteronism type II and a novel mutation (564D&#x0003e;H) in the acidic motif of the WNK4 gene. <span><span class="ref-journal">Hypertension. </span>2005;<span class="ref-vol">46</span>:295–300.</span> [<a href="/pubmed/15998707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15998707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.gong.2008.230">Gong H, Tang Z, Yang Y, Sun L, Zhang W, Wang W, Cui B, Ning G. A patient with pseudohypoaldosteronism type II caused by a novel mutation in WNK4 gene. <span><span class="ref-journal">Endocrine. </span>2008;<span class="ref-vol">33</span>:230–4.</span> [<a href="/pubmed/19016006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19016006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.gordon.1986.93">Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. <span><span class="ref-journal">Hypertension. </span>1986;<span class="ref-vol">8</span>:93–102.</span> [<a href="/pubmed/3002982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3002982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.hadchouel.2010.18109">Hadchouel J, Soukaseum C, B&#x000fc;sst C, Zhou XO, Baudrie V, Z&#x000fc;rrer T, Cambillau M, Elghozi JL, Lifton RP, Loffing J, Jeunemaitre X. Decreased ENaC expression compensates the increased NCC activity following inactivation of the kidney-specific isoform of WNK1 and prevents hypertension. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2010;<span class="ref-vol">107</span>:18109–14.</span> [<a href="/pmc/articles/PMC2964238/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2964238</span></a>] [<a href="/pubmed/20921400" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20921400</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.kahle.2004a.2064">Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP. WNK4 regulates apical and basolateral Cl- flux in extrarenal epithelia. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004a;<span class="ref-vol">101</span>:2064–9.</span> [<a href="/pmc/articles/PMC357052/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC357052</span></a>] [<a href="/pubmed/14769928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14769928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.kahle.2004b.14877">Kahle KT, Macgregor GG, Wilson FH, Van Hoek AN, Brown D, Ardito T, Kashgarian M, Giebisch G, Hebert SC, Boulpaep EL, Lifton RP. Paracellular Cl- permeability is regulated by WNK4 kinase: insight into normal physiology and hypertension. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004b;<span class="ref-vol">101</span>:14877–82.</span> [<a href="/pmc/articles/PMC522037/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC522037</span></a>] [<a href="/pubmed/15465913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15465913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.kahle.2008.91">Kahle KT, Rinehart J, Giebisch G, Gamba G, Hebert SC, Lifton RP. A novel protein kinase signaling pathway essential for blood pressure regulation in humans. <span><span class="ref-journal">Trends Endocrinol Metab. </span>2008;<span class="ref-vol">19</span>:91–5.</span> [<a href="/pubmed/18280177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18280177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.kahle.2003.372">Kahle KT, Wilson FH, Leng Q, Lalioti MD, O'Connell AD, Dong K, Rapson AK, MacGregor GG, Giebisch G, Hebert SC, Lifton RP. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">35</span>:372–6.</span> [<a href="/pubmed/14608358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14608358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.lalioti.2006.1124">Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP. WNK4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:1124–32.</span> [<a href="/pubmed/16964266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16964266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.liu.2009.12198">Liu Z, Wang HR, Huang CL. Regulation of ROMK channel and K+ homeostasis by kidney-specific WNK1 kinase. <span><span class="ref-journal">J Biol Chem. </span>2009;<span class="ref-vol">284</span>:12198–206.</span> [<a href="/pmc/articles/PMC2673288/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2673288</span></a>] [<a href="/pubmed/19244242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19244242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.liu.2011.855">Liu Z, Xie J, Wu T, Truong T, Auchus RJ, Huang CL. (Downregulation of NCC and NKCC2 cotransporters by kidney-specific WNK1 revealed by gene disruption and transgenic mouse models. <span><span class="ref-journal">Hum Mol Genet. </span>2011;<span class="ref-vol">20</span>:855–66.</span> [<a href="/pmc/articles/PMC3033178/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3033178</span></a>] [<a href="/pubmed/21131289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21131289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.louisditpicard.2012">Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Bagnis CI, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M; International Consortium for Blood Pressure (ICBP), Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet. 2012;44:456-60, S1-3. [<a href="/pubmed/22406640" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22406640</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.mansfield.1997.202">Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, Gutkin M, Vialettes B, Christofilis MA, Kauppinen-Makelin R, Mayan H, Risch N, Lifton RP. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. <span><span class="ref-journal">Nat Genet. </span>1997;<span class="ref-vol">16</span>:202–5.</span> [<a href="/pubmed/9171836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9171836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.mayan.2004.4025">Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ, Farfel Z. Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:4025–30.</span> [<a href="/pubmed/15292344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15292344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.mitani.2016.127">Mitani M, Furuichi M, Narumi S, Hasegawa T, Chiga M, Uchida S, Sato S. A patient with pseudohypoaldosteronism type II complicated by congenital hypopituitarism carrying a KLHL3 mutation. <span><span class="ref-journal">Clin Pediatr Endocrinol. </span>2016;<span class="ref-vol">25</span>:127–34.</span> [<a href="/pmc/articles/PMC5069541/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5069541</span></a>] [<a href="/pubmed/27780982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27780982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.mori.2013.30">Mori Y, Wakabayashi M, Mori T, Araki Y, Sohara E, Rai T, Sasaki S, Uchida S. Decrease of WNK4 ubiquitination by disease-causing mutations of KLHL3 through different molecular mechanisms. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2013;<span class="ref-vol">439</span>:30–4.</span> [<a href="/pubmed/23962426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23962426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.na.2012.293">Na T, Wu G, Peng J. Disease-causing mutations in the acidic motif of WNK4 impair the sensitivity of WNK4 kinase to calcium ions. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2012;<span class="ref-vol">419</span>:293–8.</span> [<a href="/pmc/articles/PMC3358818/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3358818</span></a>] [<a href="/pubmed/22342722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22342722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.na.2013.f8">Na T, Wu G, Zhang W, Dong W, Peng J. Disease-causing R1185C mutation of WNK4 disrupts a regulatory mechanism involving calmodulin binding and SGK1 phosphorylation sites. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2013;<span class="ref-vol">304</span>:F8–F18.</span> [<a href="/pmc/articles/PMC3543615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3543615</span></a>] [<a href="/pubmed/23054253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23054253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.ohta.2013.111">Ohta A, Schumacher F, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT, Alessi DR, Kurz T. The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. <span><span class="ref-journal">Biochem J. </span>2013;<span class="ref-vol">451</span>:111–22.</span> [<a href="/pmc/articles/PMC3632089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3632089</span></a>] [<a href="/pubmed/23387299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23387299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.oreilly.2003.2447">O'Reilly M, Marshall E, Speirs HJ, Brown RW. WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. <span><span class="ref-journal">J Am Soc Nephrol. </span>2003;<span class="ref-vol">14</span>:2447–56.</span> [<a href="/pubmed/14514722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14514722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.picard.2015a.e79">Picard HL, Latreche S, Thurairajasingam N, Auzan C, Fiquet B, Frayssinet R, Garnier A, Jendruchova V, Lobbedez T, Martorell L, Mortier G, Pela I, Taque S, Vargas-Poussou R, Clauser E, Jeunemaitre X. 6C.01: CULLIN-3 mutations leading to skipping of exon 9 are responsible for severe cases of familial hyperkalaemic hypertension. <span><span class="ref-journal">J Hypertens. </span>2015a;<span class="ref-vol">33</span> Suppl 1:e79.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.picard.2015b.e1">Picard HL, Thurairajasingam N, Decramer S, Girerd X, Oshaugnessy K, Mulatero P, Roussey G, Tack I, Unwin R, Vargas-Poussou R, Jeunemaitre X. 1A.01: mutations affecting the conserved acidic motif of WNK1 cause inherited normotensive hyperkalemic acidosis. <span><span class="ref-journal">J Hypertens. </span>2015b;<span class="ref-vol">33</span> Suppl 1:e1.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.ring.2007a.4020">Ring AM, Cheng SX, Leng Q, Kahle KT, Rinehart J, Lalioti MD, Volkman HM, Wilson FH, Hebert SC, Lifton RP. WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007a;<span class="ref-vol">104</span>:4020–4.</span> [<a href="/pmc/articles/PMC1805455/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1805455</span></a>] [<a href="/pubmed/17360470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17360470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.ring.2007b.4025">Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007b;<span class="ref-vol">104</span>:4025–9.</span> [<a href="/pmc/articles/PMC1803763/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1803763</span></a>] [<a href="/pubmed/17360471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17360471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.schambelan.1981.716">Schambelan M, Sebastian A, Rector FC Jr. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. <span><span class="ref-journal">Kidney Int. </span>1981;<span class="ref-vol">19</span>:716–27.</span> [<a href="/pubmed/7026872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7026872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.shekarabi.2008.2496">Shekarabi M, Girard N, Rivi&#x000e8;re JB, Dion P, Houle M, Toulouse A, Lafreni&#x000e8;re RG, Vercauteren F, Hince P, Laganiere J, Rochefort D, Faivre L, Samuels M, Rouleau GA. Mutations in the nervous system--specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II. <span><span class="ref-journal">J Clin Invest. </span>2008;<span class="ref-vol">118</span>:2496–505.</span> [<a href="/pmc/articles/PMC2398735/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2398735</span></a>] [<a href="/pubmed/18521183" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18521183</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.shibata.2013.7838">Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2013;<span class="ref-vol">110</span>:7838–43.</span> [<a href="/pmc/articles/PMC3651502/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3651502</span></a>] [<a href="/pubmed/23576762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23576762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.subramanya.2006.f619">Subramanya AR, Yang CL, Zhu X, Ellison DH. Dominant-negative regulation of WNK1 by its kidney-specific kinase-defective isoform. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2006;<span class="ref-vol">290</span>:F619–24.</span> [<a href="/pubmed/16204408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16204408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.takahashi.2014">Takahashi D, Mori T, Nomura N, Khan MZ, Araki Y, Zeniya M, Sohara E, Rai T, Sasaki S, Uchida S. WNK4 is the major WNK positively regulating NCC in the mouse kidney. <span><span class="ref-journal">Biosci Rep. </span>2014;<span class="ref-vol">34</span>(3)</span> [<a href="/pmc/articles/PMC4212913/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4212913</span></a>] [<a href="/pubmed/24655003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24655003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.tatum.2007.3887">Tatum R, Zhang Y, Lu Q, Kim K, Jeansonne BG, Chen YH. WNK4 phosphorylates ser(206) of claudin-7 and promotes paracellular Cl(-) permeability. <span><span class="ref-journal">FEBS Lett. </span>2007;<span class="ref-vol">581</span>:3887–91.</span> [<a href="/pubmed/17651736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17651736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.tsuji.2013.166">Tsuji S, Yamashita M, Unishi G, Takewa R, Kimata T, Isobe K, Chiga M, Uchida S, Kaneko K. A young child with pseudohypoaldosteronism type II by a mutation of Cullin 3. <span><span class="ref-journal">BMC Nephrol. </span>2013 Jul 31;<span class="ref-vol">14</span>:166.</span> [<a href="/pmc/articles/PMC3733749/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3733749</span></a>] [<a href="/pubmed/23902721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23902721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.vidalpetiot.2013.14366">Vidal-Petiot E, Elvira-Matelot E, Mutig K, Soukaseum C, Baudrie V, Wu S, Cheval L, Huc E, Cambillau M, Bachmann S, Doucet A, Jeunemaitre X, Hadchouel J. WNK1-related familial hyperkalemic hypertension results from an increased expression of L-WNK1 specifically in the distal nephron. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2013;<span class="ref-vol">110</span>:14366–71.</span> [<a href="/pmc/articles/PMC3761585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3761585</span></a>] [<a href="/pubmed/23940364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23940364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.wakabayashi.2013.858">Wakabayashi M, Mori T, Isobe K, Sohara E, Susa K, Araki Y, Chiga M, Kikuchi E, Nomura N, Mori Y, Matsuo H, Murata T, Nomura S, Asano T, Kawaguchi H, Nonoyama S, Rai T, Sasaki S, Uchida S. Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension. <span><span class="ref-journal">Cell Rep. </span>2013;<span class="ref-vol">3</span>:858–68.</span> [<a href="/pubmed/23453970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23453970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.wilson.2001.1107">Wilson FH, Disse-Nicod&#x000e8;me S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in WNK kinases. <span><span class="ref-journal">Science. </span>2001;<span class="ref-vol">293</span>:1107–12.</span> [<a href="/pubmed/11498583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11498583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.wilson.2003.680">Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2003;<span class="ref-vol">100</span>:680–4.</span> [<a href="/pmc/articles/PMC141056/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC141056</span></a>] [<a href="/pubmed/12515852" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12515852</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.wu.2013.1717">Wu G, Peng J. Disease-causing mutations in KLHL3 impair its effect on WNK4 degradation. <span><span class="ref-journal">FEBS Lett. </span>2013;<span class="ref-vol">587</span>:1717–22.</span> [<a href="/pmc/articles/PMC3697765/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3697765</span></a>] [<a href="/pubmed/23665031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23665031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.xu.2000.16795">Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. <span><span class="ref-journal">J Biol Chem. </span>2000;<span class="ref-vol">275</span>:16795–801.</span> [<a href="/pubmed/10828064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10828064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.xu.2005.10315">Xu BE, Stippec S, Chu PY, Lazrak A, Li XJ, Lee BH, English JM, Ortega B, Huang CL, Cobb MH. WNK1 activates SGK1 to regulate the epithelial sodium channel. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2005;<span class="ref-vol">102</span>:10315–20.</span> [<a href="/pmc/articles/PMC1177404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1177404</span></a>] [<a href="/pubmed/16006511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16006511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.yamauchi.2004.4690">Yamauchi K, Rai T, Kobayashi K, Sohara E, Suzuki T, Itoh T, Suda S, Hayama A, Sasaki S, Uchida S. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2004;<span class="ref-vol">101</span>:4690–4.</span> [<a href="/pmc/articles/PMC384808/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC384808</span></a>] [<a href="/pubmed/15070779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15070779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.yang.2003.1039">Yang CL, Angell J, Mitchell R, Ellison DH. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">111</span>:1039–45.</span> [<a href="/pmc/articles/PMC152590/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC152590</span></a>] [<a href="/pubmed/12671053" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12671053</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.yang.2007.331">Yang SS, Morimoto T, Rai T, Chiga M, Sohara E, Ohno M, Uchida K, Lin SH, Moriguchi T, Shibuya H, Kondo Y, Sasaki S, Uchida S. Molecular pathogenesis of pseudohypoaldosteronism type II: generation and analysis of a Wnk4(D561A/+) knockin mouse model. <span><span class="ref-journal">Cell Metab. </span>2007;<span class="ref-vol">5</span>:331–44.</span> [<a href="/pubmed/17488636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17488636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.zambrowicz.2003.14109">Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J. BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2003;<span class="ref-vol">100</span>:14109–14.</span> [<a href="/pmc/articles/PMC283554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC283554</span></a>] [<a href="/pubmed/14610273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14610273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pha2.REF.zhang.2013.545">Zhang C, Zhu Y, Huang F, Jiang G, Chang J, Li R. Novel missense mutations of WNK1 in patients with hypokalemic salt-losing tubulopathies. <span><span class="ref-journal">Clin Genet. </span>2013;<span class="ref-vol">83</span>:545–52.</span> [<a href="/pubmed/22934535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22934535</span></a>]</div></li></ul></div></div><div id="pha2.Chapter_Notes"><h2 id="_pha2_Chapter_Notes_">Chapter Notes</h2><div id="pha2.Author_History"><h3>Author History</h3><p>David H Ellison, MD (2017-present)<br />Kristopher T Kahle, MD, PhD; Harvard Medical School (2011-2017)<br />Frederick H Wilson, MD, PhD; Harvard Medical School (2011-2017)</p></div><div id="pha2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>16 February 2017 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 January 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 November 2011 (me) Review posted live</div></li><li class="half_rhythm"><div>25 April 2011 (ktk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK65707</span><span class="label">PMID: <a href="/pubmed/22073419" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">22073419</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/psach/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pxe/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK65707&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65707/?report=reader">PubReader</a></li><li><a href="/books/NBK65707/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK65707" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK65707" style="display:none" title="Cite this Page"><div class="bk_tt">Ellison DH. Pseudohypoaldosteronism Type II. 2011 Nov 10 [Updated 2017 Feb 16]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK65707/pdf/Bookshelf_NBK65707.pdf">PDF version of this page</a> (481K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pha2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pha2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pha2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pha2.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pha2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pha2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pha2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pha2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pha2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pha2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pha2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=65266[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">WNK4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=65125[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">WNK1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=26249[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KLHL3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8452[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CUL3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2643920" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2643920" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2643920" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2643920" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23387299" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.</a><span class="source">[Biochem J. 2013]</span><div class="brieflinkpop offscreen_noflow">The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT, Alessi DR, Kurz T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Biochem J. 2013 Apr 1; 451(1):111-22. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24821705" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice.</a><span class="source">[Hum Mol Genet. 2014]</span><div class="brieflinkpop offscreen_noflow">Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Susa K, Sohara E, Rai T, Zeniya M, Mori Y, Mori T, Chiga M, Nomura N, Nishida H, Takahashi D, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mol Genet. 2014 Oct 1; 23(19):5052-60. Epub 2014 May 12.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23576762" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4.</a><span class="source">[Proc Natl Acad Sci U S A. 2013]</span><div class="brieflinkpop offscreen_noflow">Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Proc Natl Acad Sci U S A. 2013 May 7; 110(19):7838-43. Epub 2013 Apr 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26152401" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.</a><span class="source">[Nephrol Dial Transplant. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sohara E, Uchida S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nephrol Dial Transplant. 2016 Sep; 31(9):1417-24. Epub 2015 Jul 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301424" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Dominant</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Dominant<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Harris PC, Torres VE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=22073419" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=22073419" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041900dde08911694361ab">Pseudohypoaldosteronism Type II - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Pseudohypoaldosteronism Type II - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:20:48-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D7591E04153810000000001B300AB&amp;ncbi_session=CE8D7591E0419001_0435SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK65707%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK65707&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK65707/&amp;ncbi_pagename=Pseudohypoaldosteronism Type II - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D7591E0419001_0435SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>